Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

141. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED DECEMBER 2012 – WWW.RXFILES.CA Page 1 of 4 ROCKET-AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation 1 Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS (...) 2 score 3.5), rivaroxaban 20mg po daily: ? Was non-inferior (i.e. no worse than) to warfarin for ? stroke or systemic embolism ? Had less hemorrhagic strokes, systemic embolism & bleeding (critical, fatal & intracranial) versus warfarin ? Had more drops in hemoglobin =20 g/L, tranfusions, gastrointestinal bleeding, epistaxis & hematuria versus warfarin ? At time of publication, rivaroxaban for AF is approximately $100/month; 15mg, 20mg tablets. ? A Fib, ? Warfarin + monitoring ~$35/month

RxFiles2012

142. ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation

ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED NOV 2012 – WWW.RXFILES.CA Page 1 of 3 ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation 1 Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS 2 score 2.1): • Apixaban 5mg po BID was superior to warfarin (...) for ? stroke or systemic embolism (NNT=167/1.8 years) • Apixaban, compared to warfarin, had: - ? stroke (NNT=175/1.8yr), hemorrhagic stroke (NNT=238/1.8yr) & mortality (NNT=132/1.8yr) - ? bleeding major (NNT=67/1.8yr), intracranial (NNT=128/1.8yr), other & any bleeding & ? discontinuation rates (NNT=45/1.8yr) • Net clinical benefit stroke, systemic embolism, major bleeding or death from any cause favours apixaban over warfarin (NNT=56/1.8 years) • At time of publication, apixaban is not approved by Health

RxFiles2012

143. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation

Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation Jowett S, Bryan S, Mant J, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Hobbs FD Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of anticoagulation therapy, using warfarin, compared with aspirin, for patients with atrial fibrillation aged over 75 years. The authors concluded that warfarin appeared to be cost-effective for these patients, but the differences in costs

NHS Economic Evaluation Database.2011

144. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study

Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study 21799168 2011 08 30 2011 10 24 2016 11 22 1524-4628 42 9 2011 Sep Stroke Stroke Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. 2431-5 10.1161/STROKEAHA.111.615260 Warfarin use has rapidly increased with the aging of the population. We investigated the temporal trends in the incidence and outcome of warfarin-related (...) intracerebral hemorrhages (ICHs) in a defined population. We identified all subjects with first-ever primary ICH during 1993 to 2008 among the population of Northern Ostrobothnia, Finland. The number of warfarin users was obtained from the national register of prescribed medicines kept by the Social Insurance Institution of Finland. We calculated the annual incidence of warfarin-related ICHs, 28-day case fatality, and deaths from the primary bleed. The proportion of warfarin users among the population

EvidenceUpdates2011

145. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low- or high-dose dabigatran, compared with warfarin, for the prevention of ischaemic stroke in patients aged 65 years or older, with non-valvular atrial fibrillation and risk factors for stroke. The authors concluded that dabigatran, particularly at a high

NHS Economic Evaluation Database.2011

146. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation

Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation 21512184 2011 05 30 2011 08 05 2016 11 22 1524-4628 42 6 2011 Jun Stroke Stroke Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. 1717-21 10.1161/STROKEAHA.110.600767 Oral anticoagulants are effective at reducing stroke compared with aspirin in atrial fibrillation patients older than 75 years. Although the benefits of reduced stroke risk (...) outweigh the risks of bleeding, the cost effectiveness of warfarin in this patient population has not yet been established. An economic evaluation was conducted alongside a randomized, controlled trial; 973 patients ≥75 years of age with atrial fibrillation were recruited from primary care and randomly assigned to either take warfarin or aspirin. Follow-up was for a mean of 2.7 years. Costs of thrombotic and hemorrhagic events, anticoagulation clinic visits, and primary care utilization were determined

EvidenceUpdates2011

147. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?

Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? Page SP, Siddiqui MS, Finlay M, Hunter RJ, Abrams DJ, Dhinoja M, Earley MJ, Sporton SC, Schilling RJ Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the costs and effectiveness of catheter ablation, without intracardiac echocardiography, for adults with atrial fibrillation, who were on uninterrupted warfarin. The authors concluded that uninterrupted warfarin was effective and safe

NHS Economic Evaluation Database.2011

148. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial.

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. 21576658 2011 06 02 2011 08 02 2015 11 19 1524-4539 123 21 2011 May 31 Circulation Circulation Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant (...) therapy (RE-LY) trial. 2363-72 10.1161/CIRCULATIONAHA.110.004747 Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median

EvidenceUpdates2011

149. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial 21282540 2011 03 09 2011 05 09 2013 11 21 1527-7755 29 8 2011 Mar 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 986-93 (...) 10.1200/JCO.2010.31.6844 In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens. A total of 667 patients with previously untreated myeloma who received thalidomide-containing regimens and had

EvidenceUpdates2011

150. Genetic warfarin dosing tables versus algorithms

Genetic warfarin dosing tables versus algorithms 21272753 2011 01 28 2011 03 07 2017 02 20 1558-3597 57 5 2011 Feb 01 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Genetic warfarin dosing: tables versus algorithms. 612-8 10.1016/j.jacc.2010.08.643 The aim of this study was to compare the accuracy of genetic tables and formal pharmacogenetic algorithms for warfarin dosing. Pharmacogenetic algorithms based on regression equations can predict warfarin dose, but they require (...) detailed mathematical calculations. A simpler alternative, recently added to the warfarin label by the U.S. Food and Drug Administration, is to use genotype-stratified tables to estimate warfarin dose. This table may potentially increase the use of pharmacogenetic warfarin dosing in clinical practice; however, its accuracy has not been quantified. A retrospective cohort study of 1,378 patients from 3 anticoagulation centers was conducted. Inclusion criteria were stable therapeutic warfarin dose

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

151. Randomized Trial of a Warfarin Communication Protocol for Nursing Homes: an SBAR-based Approach

Randomized Trial of a Warfarin Communication Protocol for Nursing Homes: an SBAR-based Approach 21295198 2011 02 07 2011 03 14 2016 10 19 1555-7162 124 2 2011 Feb The American journal of medicine Am. J. Med. Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach. 179.e1-7 10.1016/j.amjmed.2010.09.017 More than 1.6 million Americans currently reside in nursing homes. As many as 12% of them receive long-term anticoagulant therapy with warfarin. Prior (...) research has demonstrated compelling evidence of safety problems with warfarin therapy in this setting, often associated with suboptimal communication between nursing home staff and prescribing physicians. We conducted a randomized trial of a warfarin management protocol using facilitated telephone communication between nurses and physicians in 26 nursing homes in Connecticut in 2007-2008. Intervention facilities received a warfarin management communication protocol using the approach "Situation

EvidenceUpdates2011

153. Home Monitoring of Warfarin Effects.

Home Monitoring of Warfarin Effects. Home monitoring of warfarin effects. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21268733 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Jan 27;364(4):378; author reply 378-9. doi: 10.1056/NEJMc1012980#SA2. Home monitoring of warfarin effects. , . Comment on [N Engl J Med. 2010] PMID: 21268733 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links

NEJM2011 Full Text: Link to full Text with Trip Pro

154. Home Monitoring of Warfarin Effects.

Home Monitoring of Warfarin Effects. Home monitoring of warfarin effects. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21268734 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Jan 27;364(4):378; author reply 378-9. doi: 10.1056/NEJMc1012980#SA1. Home monitoring of warfarin effects. . Comment on [N Engl J Med. 2010] PMID: 21268734 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You

NEJM2011 Full Text: Link to full Text with Trip Pro

155. Randomised controlled trial: In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding

Randomised controlled trial: In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding Article

Evidence-Based Medicine (Requires free registration)2011

156. Apixaban versus warfarin in patients with atrial fibrillation.

Apixaban versus warfarin in patients with atrial fibrillation. 21870978 2011 09 15 2011 09 27 2014 11 20 1533-4406 365 11 2011 Sep 15 The New England journal of medicine N. Engl. J. Med. Apixaban versus warfarin in patients with atrial fibrillation. 981-92 10.1056/NEJMoa1107039 Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce (...) the risk of stroke in a similar population in comparison with aspirin. In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing

NEJM2011

157. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 21830957 2011 09 08 2011 09 16 2016 03 07 1533-4406 365 10 2011 Sep 08 The New England journal of medicine N. Engl. J. Med. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 883-91 10.1056/NEJMoa1009638 The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent (...) and predictable anticoagulation than warfarin. In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism. In the primary analysis, the primary end point occurred in 188

NEJM2011

158. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial.

Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. 21700651 2011 06 24 2011 11 08 2017 02 20 1756-1833 342 2011 Jun 23 BMJ (Clinical research ed.) BMJ Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. d3653 10.1136/bmj.d3653 bmj.d3653 To compare the predictive power of the main existing and recently proposed schemes (...) for stratification of risk of stroke in older patients with atrial fibrillation. Comparative cohort study of eight risk stratification scores. Trial of thromboprophylaxis in stroke, the Birmingham Atrial Fibrillation in the Aged (BAFTA) trial. 665 patients aged 75 or over with atrial fibrillation based in the community who were randomised to the BAFTA trial and were not taking warfarin throughout or for part of the study period. Events rates of stroke and thromboembolism. 54 (8%) patients had an ischaemic stroke

BMJ2011 Full Text: Link to full Text with Trip Pro

159. Oral anticoagulation with warfarin - 4th edition

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site you agree to us using cookies as described in Navigate this article Previous article in issue: Secondary cancers following allogeneic haematopoietic cell transplantation in adults Next article in issue: Lenalidomide downregulates the cell survival factor, interferon regulatory (...) publications since 2005. Publications known to the writing group were supplemented with additional papers identified by searching PubMed for publications in the last 5 years using the key word warfarin and limits clinical trial, randomized control trial, meta-analysis, humans, core clinical journals, and English language. The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemostasis and Thrombosis Task Force of the British Committee for Standards

British Committee for Standards in Haematology2011

160. The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review

The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review "The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Pa" by Karim Bouferrache < > > > > > Title Author Date of Award 4-20-2011 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Patients with atrial fibrillation are at increased risk of experiencing embolic events. Anticoagulation therapy (...) is known to reduce these events. Warfarin, the only oral anticoagulant available, gives inconsistent results, and thus requires frequent laboratory monitoring and adjustment. A newly FDA approved fixed-dosage direct thrombin inhibitor, dabigatran, has shown some promising results in efficacy and safety. Method: An extensive review of the literature search was performed using the following database: Web of Science, MEDLINE and CINHAL. Two studies met the inclusion and exclusion criteria and were

Pacific University EBM Capstone Project2011